IND Approval_Providing professional financial news and data related to IND Approval, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

HAIXI PHARMA (02637.HK): IND Application of HXP089 for Glioblastoma Approved by NMPA

Tags：

HAIXI PHARMA 02637.HK IND Approval

2026-07-14

Finance
Dongjiang Environmental (00895.HK): 2026 Interim Performance Forecast, Expected Net Loss of RMB 250 Million to RMB 270 Million
Finance
CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
Finance
China Everbright Water (01857.HK): Completes Issuance of Phase 1 Medium-Term Notes of 2026 with Principal of RMB 1.5 Billion
Finance
MicroTech Medical(02235.HK): Continuous Glucose Monitoring System Secures Marketing Approval in South Korea
Finance
Overseas Chinese Town Asia (03366.HK): 100% Equity Interest in Huizhou Project Put Up for Public Listing Sale, Winning Bid Price at Approximately RMB 307 Million
Finance
Sino Biopharmaceutical (01177.HK): TRD205 (AT2R Antagonist) Included in CDE’s Breakthrough Therapy Designation List
Finance
Weigao Group(01066.HK): Controlling Shareholder Adds Approximately 15.5988 Million H Shares, Cumulative Share Purchase Hits Around 30.55 Million Shares
Finance
China Nonferrous Mining (01258.HK): Positive Profit Forecast, Interim Profit Attributable to Owners Expected to Rise by Approximately 60%
Finance
CT Vision (International) Holdings(00994.HK): Establishes American Depositary Receipt Programme with Ticker Symbol "CTVHY"
Finance
China Innovation Investment (01217.HK): Profit Warning, Expected Interim Loss of Approximately HK$61 Million

Scan QR Code

Download App